Discussion Agenda

Memorandum and resolution re: Final Rule to Revise 12 CFR 360.10 and Associated Delegations of Authority.

Memorandum and resolution re: Board Briefings on Certain Merger and Deposit Insurance Applications Outstanding for More Than 270 Days.

CONTACT PERSON FOR MORE INFORMATION: Direct requests for further information concerning the meeting to Debra A. Decker, Executive Secretary of the Corporation, at 202–898–8748.

Authority: 5 U.S.C. 552b.

Dated at Washington, DC, on June 20, 2024.

Federal Deposit Insurance Corporation.

James P. Sheesley,

Assistant Executive Secretary.

[FR Doc. 2024–13950 Filed 6–25–24; 8:45 am]

BILLING CODE 6714–01–P

FEDERAL RESERVE SYSTEM

[Docket No. OP–1831]

Expanded Hours for Fedwire Funds Service & National Settlement Service

AGENCY: Board of Governors of the Federal Reserve System.

ACTION: Request for comment; extension of comment period.

SUMMARY: On May 9, 2024, the Board of Governors of the Federal Reserve System (Board) published in the **Federal Register** a proposal to expand the operating hours of the Fedwire® Funds Service and the National Settlement Service (NSS). The Board proposed to expand the operating hours of the Fedwire Funds Service to 22 hours per day, 7 days per week, every day of the year (22x7x365) and to correspondingly expand the operating hours of NSS, with NSS closing 30 minutes earlier than the Fedwire Funds Service. The proposal provided for a comment period ending on July 8, 2024. The Board is extending the comment period for 60 days, until September 6, 2024.

DATES: The notification published on May 9, 2024 (89 FR 39613), is extended. Comments must be received by September 6, 2024.

ADDRESSES: You may submit comments by any of the methods identified in the proposal.

FOR FURTHER INFORMATION CONTACT: Mark Magro, Manager, Division of Reserve Bank Operations and Payment Systems (202–452–3944); Ann Sun, Lead Financial Institution Policy Analyst, Division of Reserve Bank Operations and Payment Systems (202–912–7938); Gavin Smith, Senior Counsel, Legal Division (202 452–3474); or Corinne Milliken Van Ness, Senior Counsel, Legal Division (202–452–2421), Board of Governors of the Federal Reserve System. For users of TTY–TRS, please call 711 from any telephone, anywhere in the United States.

SUPPLEMENTARY INFORMATION: On May 9, 2024, the Board of Governors of the Federal Reserve System (Board) published a proposal to expand the operating hours of the Fedwire® Funds Service and the National Settlement Service (NSS) in the **Federal Register**. The Board proposed to expand the operating hours of the Fedwire Funds Service to 22 hours per day, 7 days per week, every day of the year (22x7x365) and to correspondingly expand the operating hours of the NSS, with the NSS closing 30 minutes earlier than the Fedwire Funds Service.[1]

The proposal provided for a comment period ending on July 8, 2024. The Board is extending the comment period for 60 days, until September 6, 2024. Since the publication of the proposal, the Board has received comments requesting an extension of the comment period. An extension of the comment period will provide additional opportunity for interested parties to analyze the proposal and prepare and submit comments. Therefore, the Board is extending the end of the comment period for the proposal from July 8, 2024, to September 6, 2024.

By order of the Board of Governors of the Federal Reserve System, acting through the Secretary of the Board under delegated authority.

Ann E. Misback,

Secretary of the Board.

[FR Doc. 2024–14018 Filed 6–25–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–N–2886]

Food and Drug Administration Information Technology Strategy and Customer Experience Strategy; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for comment.

SUMMARY: The Food and Drug Administration (FDA or Agency) is requesting comments on its ''Information Technology (IT) Strategy'' and ''Customer Experience (CX) Strategy.'' In accordance with the Agency's User Fee Program commitments and Omnibus Bill requirements, FDA must annually update and publish its IT Strategy by September 30. The initial strategy, released in September 2023, outlines the future direction of FDA's data and technology capabilities. A key objective of FDA's IT Strategy is to modernize enterprise services and capabilities to improve customer experience. The FDA CX Strategy was created to guide this effort. This comprehensive enterprise plan introduces the Agency's CX framework and considers the perspective of interested parties such as the public, employees, and industry.

DATES: Submit either electronic or written comments on the IT Strategy by July 31, 2024, to ensure that the Agency considers your comments for future iterations of the IT Strategy.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov*. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov*.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management

[1] 89 FR 39613 (May 9, 2024).

Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked, and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2024–N–2886 for ''FDA IT Strategy and CX Strategy.'' Received comments will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov*. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf*.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

Submit written requests for single copies of this IT Strategy & CX Strategy to the Office of Digital Transformation, Food and Drug Administration, FDA Library, 5630 Fishers Lane, Rm. 1087, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your request or include a fax number to which the IT Strategy or CX Strategy may be sent. See the **SUPPLEMENTARY INFORMATION** section for information on electronic access to the IT Strategy or CX Strategy.

FOR FURTHER INFORMATION CONTACT: Casi Alexander, Office of Digital Transformation, Food and Drug Administration, FDA Library, 5630 Fishers Lane, Rm. 1087, Rockville, MD 20857, 240–402–5171, email: *Casi.Alexander@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a request for comment on its strategies entitled ''FDA Information Technology Strategy'' and ''Customer Experience Strategy.''

As part of FDA's fulfillment of requirements in section 3627 of the Consolidated Appropriations Act, 2023 (Pub. L. 117–328), and commitments described in section IV.A.2. of the ''PDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023–2027'' (PDUFA VII commitment letter), FDA is developing a comprehensive framework for guiding the Agency's work and allocating annual technology budgets and resources. The announcement of the availability of the first Agency-wide IT Strategy was published in the **Federal Register** on September 13, 2023 (88 FR 64435). As part of an annual strategic planning process, FDA reviewed the strategy and made minor updates to align with internal and external changes. FDA's 2024 refresh of the IT Strategy required no change to its IT goals and minimal changes listed below:

• Updated 14 objectives to increase clarity;

• Highlighted our commitment to working with global public health partners and advocating for global standards;

• Clarified mission outcomes the IT Strategy aims to drive; and

• Promoted alignment to relevant strategies, *e.g.,* those of the Department of Health and Human Services.

For additional context on how the IT Strategy will be executed, FDA suggests reading the IT Operating Plan, a companion document to the IT Strategy. The IT Operating Plan, published in February 2024, is a blueprint designed to guide FDA's technological growth and development in accordance with the IT strategic goals. It encompasses an IT strategic roadmap, governance, and organization construct as well as a performance measurement process designed to advance public health outcomes.

One of FDA's IT strategic goals is to ''Modernize Enterprise Services and Capabilities'' which includes an objective to improve customer experience. This objective is focused on creating customer-centric solutions that enhance satisfaction by improving accessibility to IT solutions, streamlining processes, and easing adoption. The CX Strategy was developed to outline FDA's approach to make progress against this objective. The CX Strategy introduces the Agency's CX framework and is written with the perspective of interested parties from the public, employees, and industry in mind.

The Agency continues to take a collaborative approach to strategy development by gathering input from numerous internal and external interested parties. This input is crucial for developing an updated comprehensive plan that best meets the needs and goals of industry and the Agency. Comments on the IT Strategy as well as the CX Strategy will be considered for future iterations.

II. Requested Feedback

Interested persons are invited to provide detailed comments to the Office of Digital Transformation (see **ADDRESSES**) on the specific IT Strategy Goals and Objectives within FDA's Agency-wide IT Strategy as well as the CX Strategy. To facilitate comment, FDA has developed a series of questions in this section. The questions are not meant to be exhaustive, and FDA is also interested in any other pertinent information interested parties would like to share on this topic. FDA encourages interested parties to provide the specific rationale and basis for their comments, including any available supporting data and information.

A. IT Strategy and Operating Plan

This annual update to the IT Strategy contains minimal changes per the summary above. If you previously responded to the Agency's **Federal Register** notice published on September 13, 2023 (88 FR 64435), soliciting feedback, you will see some similar questions. You may choose to refer to your prior response or to provide additional feedback based on your experience since the first IT Strategy publication as well as context provided in our IT Operating Plan, a companion guide to the IT Strategy.

1. Which goals and objectives are most important to you? Why?

2. What are up to three outcomes the IT Strategy has helped or will help you achieve? Please provide examples.

3. What gaps do you see in the IT Strategy?

4. What challenges or risks do you foresee in executing the IT Strategy beyond those captured in the IT Operating Plan?

5. How have you leveraged the IT Strategy and/or IT Operating Plan since they were published in 2023?

6. How might FDA continue to communicate and engage interested parties in developing and implementing the strategy?

B. Customer Experience Strategy

1. Which goals and objectives are most important to you? Why?

2. What gaps do you see in the CX Strategy's goals or objectives?

3. What has been your customer experience when interacting with FDA?

4. What is one thing FDA can do to improve your customer experience?

III. Electronic Access

Persons with access to the internet may obtain electronic versions of the IT Strategy and CX Strategy at *https://www.regulations.gov* and the IT Operating Plan at *https://www.fda.gov/about-fda/office-digital-transformation/odt-reports*.

Dated: June 20, 2024.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2024–13941 Filed 6–25–24; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2023–D–3740]

Priority Zoonotic Animal Drug Designation and Review Process; Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry #283 entitled ''Priority Zoonotic Animal Drug Designation and Review Process.'' This guidance is intended to assist sponsors pursuing Priority Zoonotic Animal Drug (PZAD) designation for a new animal drug. This guidance is intended to provide the eligibility criteria for PZAD designation, the process for requesting PZAD designation, and enhancements in the FDA review process for PZADs.

DATES: The announcement of the guidance is published in the **Federal Register** on June 26, 2024.

ADDRESSES: You may submit either electronic or written comments on Agency guidances at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov*.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2023–D–3740 for ''Priority Zoonotic Animal Drug Designation and Review Process.'' Received comments will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.*

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of the guidance to the Policy and Regulations Staff (HFV–6), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT: Evgenij Evdokimov, Center for Veterinary Medicine (HFV–108), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–402–0712, *evgenij.evdokimov@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: